Prothrombin Complex Concentrate Such as Therapy and Prophylaxis in Factor X-Deficient Patient (Friuli Variant)

Abstract

Background: Factor X (FX) deficiency is a serious, rare bleeding disorder, with 1 in 500 000 affected people. Hemorrhages, hematuria, epistaxis, and other bleeding complications are frequent. Case Report: Now, we report a case of a well-known 77-year-old FX-deficient patient (Friuli variant, level <1%, mutation Pro³⁴³→Ser, exon VIII) with hypertension, chronic obstructive pulmonary disease (COPD), and chronic gastritis, admitted many times to hospital due to surgical complications after aortic abdominal aneurysm (AAA) repair. Use of prothrombin complex concentrate (PCC) such as hemostatic therapy during surgeries and prophylaxis after discharge is shown in this article. Three consecutive surgeries were considered. First, endoleak postendoprosthesis; second, AAA breakage; and third, planned surgery, a new endovascular prosthesis positioning and femur-femoral bypass. No adverse events due to PCC were found by local physicians. Discussion: We discuss the methods commonly used in the treatment and prophylaxis of patients with FX deficiency to reduce hemorrhagic risk and to improve their quality of life. Conclusion: Waiting for specific therapeutic options for FX deficiency, currently, the best treatment is represented by PCC. Its correct use permits an improvement in life quality and a reduction in bleeding frequency in FX-deficient patients.

Keywords

factor X deficiency factor X—Friuli variant bleeding disorders prothrombin complex concentrate thromboprophylaxis

References

Peyvandi F. , Mannucci PM Rare bleeding disorders. Thromb Haemost. 1999 ;82(4):1207-1214.

Peyvandi F. , Kaufman RJ , Seligsohn U. , et al. Rare bleeding disorders. Haemophilia. 2006;12(suppl 3):137-142.

Peyvandi F. , Cattaneo M. , Inbal A. , De Moerloose P. , Spreafico M. Rare bleeding disorders. Haemophilia. 2008 ;14(suppl3):202-210.

Grham JB Stuart factor: discovery and designation as factor X. J Thromb Haemost. 2003;1(5):871-877.

Uprichard J. , Perry DJ Factor X deficiency. Blood Rev. 2002; 16(2):97-110.

Herrmann FH , Auerswald G. , Ruiz-Saez A. , et al, and the Greifswald Factor X Deficiency Study Group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene . Haemophilia. 2006;12(5):479-489.

Mishra P. , Naithani R. , Dolai T. , et al. Intracranial haemorrhage in patients with congenital haemostatic defects. Haemophilia. 2008; 14(5):952-955.

Ma JF , Coutre SE , Curet MJ , Brooks JD Refractory hematuria from amyloidosis successfully treated by splenoctomy . Urology. 2006;67(5):1085.e13-1085.

Dadhwal V. , Deka D. , Ghosh B. , Mittal S. Recurrent ovarian haemorrhage in a girl with congenital factor X deficiency . Haemophilia. 2008;14(4):853-855.

10.

Saxena R. , Gupta M. , Gupta PK , Kashyap R. , Choudhry VP , Bhargava M. Inherited bleeding disorders in Indian women with menorrhagia. Haemophilia. 2003;9(2):193-196.

11.

Girolami A. , Scandellari R. , Scapin M. , Vettore S. Congenital bleeding disorders of the vitamin k-dependent clotting factors. Vitam Horm. 2008;78:281-374.

12.

Chiossi G. , Spero JA , Esaka EJ , et al. Plasma exchange in a case of severe factor X deficiency in a pregnancy: critical review of the literature. Am J Perinatol . 2008;25(3):189-192.

13.

Samama CM Prothrombin complex concentrates: a brief review. Eur J Anaesthesiol . 2008;25(10):784-789.

14.

Di Paola J. , Nugent D. , Young G. Current therapy for rare factor deficiencies . Haemophilia. 2001 ;7(suppl 1):16-22.

15.

Bolton-Maggs PHB , Perry DJ , Chalmers EA , et al. The rare coagulation disorders - review with guidelines for management from United Kingdom Haemophilia Centre Doctor’s Organisation. Haemophilia. 2004;10(5):593-628.

16.

Fair DS , Revak DJ , Hubbard JG , Girolami A. Isolation and characterization of the factor X Friuli variant. Blood. 1989;73(8): 2108-2116.

17.

Girolami A. , Randi ML , Tezza F. , Molaro G. , Girolami B. Unusual longevity in a patient with factor X Friuli coagulation disorder. Thromb Hemost. 2005;93(2):385-387.

18.

Menegatti M. , Peyvandi F. Factor X deficiency. Semin Thromb Hemost. 2009;35(4):407-415.

19.

Brown DL , Kouides PA Diagnosis and treatment of inherited factor X deficiency. Haemophilia. 2008;14(6):1176-1182.

20.

Dann CJ , Goa KL Tranexamic Acid. A review of its use in surgery and other indications . Drugs. 1999;57(6):1005-1032.

21.

Keeling D. , Tait C. , Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Centre Doctor’s Organisation (UKHCDO) guideline approved by the British Committee for standards in haematology. Haemophilia. 2008;14(4):671-684.

22.

Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency . Thromb Res . 1999;95(4suppl1):S7-S12.

23.

Takabe K. , Holman PR , Herbst KD , Glass CA , Bouvet M. Successful perioperative management of factor X deficiency associated with primary amyloidosis. J Gastrointest Surg. 2004; 8(3):358-362.

24.

McMahon C. , Smith J. , Goonan C. , Byrne M. , Smith OP The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency. Br J Haematology. 2002;119(3): 789-791.

25.

Kouides PA , Kulzer L. Propyilactic treatment of severe factor X deficiency with prothrombin complex concentrate. Haemophilia. 2001;7(2):220-223.

26.

Sandler E. , Goss S. Prevention of recurrent intracranial hemorrhage in a factor X-deficient infant . Am J Pediatr Hematol Oncol. 1992 ;14(2):163-165.